Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
You can be forgiven for doing a double-take on Intuitive Surgical (ISRG) on Friday. The company posted second-quarter revenue of $2.89 billion, up 19% from a year ago and comfortably ahead of Wall Street estimates. Yet the stock ended the day down 14.1%, closing at a new 52-week low.
The surgical robotics giant beat estimates, but a moderation in its core US market has investors questioning the whole story.
Jim Cramer took a bullish stance on Alibaba despite its brutal year-to-date slide, pairing the call with two steady compounders he thinks belong in every long-term portfolio. Here is what he told one caller sitting on a sizable BABA position.
JNJ raised its 2026 outlook after strong Q2 results, but can new medicines and pipeline strength outweigh patent losses and MedTech challenges?
For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.
Despite its enticing dividend yield and relatively attractive valuation, J&J Snack Foods' (JJSF) stock may represent a value trap.
For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.
J&J has more than 28 sources of blockbuster revenue.
They can help stabilize your portfolio in these otherwise volatile times.
DePuy Synthes, part of Johnson & Johnson MedTech, has acquired spine surgery company Expanding Innovations, adding new expandable interbody technologies to its portfolio. Johnson & Johnson has received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform in electrophysiology, expanding its ablation technology offering. For investors watching Johnson & Johnson, ticker NYSE:JNJ, these MedTech moves arrive with the stock at $253.04 and a value_score of 2. The company has recorded...
All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very different stories about where each stock goes from here.
A portfolio paying $55,000 this year feels useful today, but inflation has a way of quietly making that same paycheck feel smaller every year you spend it. The yield you choose right now could either protect your retirement income or slowly hollow it out.
Most investors chase the biggest dividend check they can find today, but that instinct quietly sabotages the income they could be collecting a decade from now. The math behind a smarter approach is almost offensively simple once you see it.
The typical American household spent $78,535 in 2024. Headline PCE inflation was running at 4.1% year over year in May 2026, which means the same lifestyle can become thousands of dollars more expensive in a single year. Social Security benefits are rising 2.8% in 2026, but that adjustment may not fully offset the higher cost ... The Portfolio That Lets You Ignore Inflation
Most investors chase the biggest yield they can find, but the portfolio that actually grows your income year after year is built on a completely different logic. Here is how dividend math quietly delivers something that usually requires a performance review.
Every new tariff headline, rate decision, and earnings miss seems to demand a financial response, and that constant pressure is exhausting. There is a way to build a portfolio so sturdy that the daily news cycle loses its grip on your nerves.
July has a long history of punishing investors who mistake a good run for a durable business. Three Dividend Kings have kept raising their payouts through every major crash since 1987, and all three just delivered beat-and-raise quarters heading into a summer that already feels shaky.
A single executive certificate at a top business school can run well into five figures. A week at a professional conference with airfare and hotel can easily clear several thousand dollars. But lifelong learning does not have to mean elite programs and corporate travel. It can also mean finishing a college degree, taking community college ... Here’s the Funding It Takes to Keep Learning Forever
DIVO's covered-call strategy looks solid on paper, but two macro forces are quietly working against its monthly payouts in ways most income investors overlook. Here is what the options chain and the Treasury market are signaling right now.
The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.
Cramer named specific sectors he's betting on for late 2026 while calling out two popular investments as traps that investors should exit now, regardless of where they bought in.
DGRO's next index rebalance could quietly shift millions of dollars across healthcare and financials, and one overlooked holding sits at the center of the trade. Here is why the December reconstitution deserves more attention than investors are giving it.
With 10-year Treasuries near 4.62%, VYM's $94.6 billion portfolio faces a real test from risk-free yields, and two familiar names inside the fund are quietly raising red flags about future income growth.